Shares in Ciphergen Sink 18 Percent on News of Second Class-Action Suit | GenomeWeb

NEW YORK, Dec. 7 (GenomeWeb News) - Shares in Ciphergen Biosystems were down 18.26 percent, or $.21, at $.94 in heavy mid-afternoon trading after the company confirmed that it is the target of a class-action lawsuit.


Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: miR-515 levels higher in women with preeclampsia, horizontal gene transfer in parasitic plants, and more.

A cancer researcher retracts 19 articles from one journal for image manipulation, according to Retraction Watch.

Precision medicine has to consider context in addition to genetic mutations in cancer treatment, Medscape reports.

Genomics may help the Cavendish banana from succumbing to fungal infections, a trio of researchers writes at the Conversation.